<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618176</url>
  </required_header>
  <id_info>
    <org_study_id>2004BA719A10</org_study_id>
    <secondary_id>2004BA719A10</secondary_id>
    <nct_id>NCT00618176</nct_id>
  </id_info>
  <brief_title>Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the three generic nevirapine-based
      antiretroviral regimens are effective in the treatment of Acquired immune deficiency syndrome
      .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)</intervention_name>
    <description>Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W&gt;60Kg)125mg bid (W&lt;60Kg) Nevirapine (NVP) 200mg bid</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)</intervention_name>
    <description>Stavudine (d4T) 30mg bid (W&gt;60Kg)20mg bid (W&lt;60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)</intervention_name>
    <description>Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  the subjects were HIV-seropositive by standard serum enzyme-linked immunosorbent assay
             (ELISA) tests and also by Western blot analysis

          -  the subjects were antiretroviral drug-naïve

          -  a baseline CD4+ T-cell count from 100 to 350 cells/mm3 and a baseline plasma viral
             load over 500copies/ml

        Exclusion Criteria:

          -  pregnancy or breastfeeding

          -  anticipated nonadherence

          -  AIDS-defining illness within 2 weeks of entry

          -  white blood cell count less than 2.0×109/L, absolute neutrophil count less than
             1.0×109/L, hemoglobin level less than 90g/l, platelet count less than 0.75×1012/L

          -  transaminase and alkaline phosphatase level more than 3 times the upper limit of the
             normal range, bilirubin level more than 2.5times the upper limit of the normal range,
             serum creatinine level more than 1.5 times the upper limit of the normal range
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2008</study_first_submitted>
  <study_first_submitted_qc>February 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <last_update_submitted>March 21, 2008</last_update_submitted>
  <last_update_submitted_qc>March 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Taisheng Li</name_title>
    <organization>Peking Union Medical College Hospital</organization>
  </responsible_party>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>adverse effects</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Drug Resistance, Viral</keyword>
  <keyword>treatment naïve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Stavudine</mesh_term>
    <mesh_term>Didanosine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

